Susana Barbosa-Méndez
Alberto Salazar-Juárez*†- Subdirección de Investigaciones Clínicas, Laboratorio de Neurofarmacología Conductual, Microcirugía y Terapéutica Experimental, Instituto Nacional de Psiquiatría, Ciudad de México, Mexico
Introduction: Chronic cocaine exposure induces an increase in dopamine release and an increase in the expression of the Fos protein in the rat striatum. It has been suggested that both are necessary for the expression of cocaine-induced alterations in behavior and neural circuitry. Mirtazapine dosing attenuated the cocaine-induced psychomotor and reinforcer effects.
Methods: The study evaluates the effect of chronic dosing of mirtazapine on cocaine-induced extracellular dopamine levels and Fos protein expression in rats. Male Wistar rats received cocaine (10 mg/Kg; i.p.) during the induction and expression of locomotor sensitization. The mirtazapine (30 mg/Kg; MIR), was administered 30 minutes before cocaine during the cocaine withdrawal. After each treatment, the locomotor activity was recorded for 30 minutes. Animals were sacrificed after treatment administration. Dopamine levels were determined by high-performance liquid chromatographic (HPLC) in the ventral striatum, the prefrontal cortex (PFC), and the ventral tegmental area (VTA) in animals treated with mirtazapine and cocaine. The quantification of c-fos immunoreactive cells was carried out by stereology analysis.
Results: Mirtazapine generated a decrease in cocaine-induced locomotor activity. In addition, mirtazapine decreased the amount of cocaine-induced dopamine and the number of cells immunoreactive to the Fos protein in the striatum, PFC, and VTA.
Discussion: These data suggest that mirtazapine could prevent the consolidation of changes in behavior and the cocaine-induced reorganization of neuronal circuits. It would explain the mirtazapine-induced effects on cocaine behavioral sensitization. Thus, these data together could support its possible use for the treatment of patients with cocaine use disorder.
1 Introduction
Cocaine use disorder (CUD) is a significant health problem worldwide (1). There are currently no FDA-approved drugs for treatment (2).
Various studies in rodents have described that cocaine produces its psychomotor and reinforcing effects primarily by blocking the dopamine transporter (DAT) (3); this action increases extracellular dopamine levels in the striatum (4, 5), which leads to the activation of dopamine D1 and D2 receptors in the striatum, ventral-tegmental area (VTA) and prefrontal cortex (PFC) (6). However, several studies support that dopamine D1 receptors are necessary to mediate the cocaine-induced behavioral, cellular, and molecular effects (7–9).
In this sense, pioneering studies have documented that repeated cocaine exposure induces an increase in the expression of the Fos protein in the rat striatum (10–12). The c-fos gene belongs to the early expression genes (IEG) (13–15). IEGs encode transcription factors (Fos, FosB) or effector proteins (Arc, Homer) involved in various brain functions. Still, it has been suggested that they are the link that ensures the continuity between rapid synaptic changes and the adaptations required for neural plasticity (16–18). In the case of the c-fos gene and the Fos protein, they have been associated with cell proliferation, differentiation, transformation, and death (15, 19).
Several studies have reported that the expression of the c-fos gene is related to the persistent changes induced by cocaine (20, 21). These studies suggest that the c-Fos gene is an intracellular regulator of cocaine-induced alterations in gene expression, reorganization of neural circuitry, and expression of behavioral sensitization (22, 23).
In addition, animal studies have shown that various external stimuli that increase neuronal activity induce c-fos expression (15, 24). These studies show that in the basal condition, the constitutive levels of c-fos are low. Still, in response to an external stimulus, the c-fos levels increase rapidly and return to their basal level in a matter of hours. This property has given the expression of the c-fos gene to be considered an important experimental tool as a marker of neuronal activity (15, 25).
On the other hand, we have recently reported a series of pre-clinical and clinical studies (26, 27), which evaluated the efficacy of mirtazapine (MSD REMERON, Schering-Plough-Organon, USA), an effective noradrenergic and a specific serotoninergic antidepressant with pronounced early anxiolytic effects in patients with moderate-to-severe depression (28, 29) to attenuate the reinforcing and psychomotor effects of cocaine, nicotine, and heroin, in rodents and humans (27, 30–34).
These studies showed that dosing of mirtazapine in rodents decreases cocaine- and nicotine-induced locomotor activity (27, 30, 32), attenuates the induction and expression of methamphetamine-, morphine-, nicotine-, and cocaine-induced locomotor sensitization (27, 30, 35, 36) and place preference (CPP) (35 37–37), and reduces self-administration of methamphetamine, cocaine, nicotine, and heroin (31, 33, 34, 38, 39). 30 mg/Kg of mirtazapine decreases depression- and anxiety-like behaviors during cocaine withdrawal (40). In humans, mirtazapine reduces alcohol, cocaine, and methamphetamine abuse (26, 41–43). It also improves symptoms of depression, anxiety, and insomnia during benzodiazepine, methamphetamine, alcohol, and cocaine withdrawal (26, 41, 43–45).
Thus, given that chronic exposure to cocaine induces an increase in extracellular dopamine levels through the blockade of DATs (4) and it produces the expression of early expression genes (c-fos) via activation mainly of dopamine D1 receptors (9) and since both, the increase in dopamine levels and the expression of the Fos protein are necessary for the expression of cocaine-induced alterations in behavior and neural circuitry (22, 23) and since the expression of c-fos is considered a marker of neuronal activity (15), and since mirtazapine is effective in attenuating the cocaine-induced psychomotor and reinforcers effects (34), then it would be important to evaluate the effect of chronic dosing of mirtazapine on the cocaine-induced extracellular dopamine levels and Fos protein expression in rats.
2 Materials and methods
2.1 Animals
We used male Wistar rats weighing 250–280 g at the beginning of the study. They were housed in groups of four in standard plastic rodent cages (57 cm x 35 cm x 20 cm) in a colony room maintained at constant temperature (21 ± 2°C) and humidity (40–50%) on a 12:12-h light/dark cycle (lights on at 7:00 a.m.) for an acclimation period of 3 days. During this period, the animals had continuous access to rodent chow pellets and water, except during the experimental sessions. All experiments took place during the light phase of the light/dark cycle (between 9:00 a.m. and 7:00 p.m.). The Institutional Animal Care- and Bioethics Committee approved the procedures (CEI/C/IC092020/2006) in strict compliance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH).
2.2 Drugs
The Mexican government kindly donated cocaine hydrochloride (COC) under strict regulatory controls. All drugs used in experimental animals were kept under official surveillance (COFEPRIS- LC-0004-2003). Mirtazapine (MIR; Remeron, Schering-Plough-Organon-SANFER), was purchased after obtaining the required regulatory permission, as per official guidelines (COFEPRIS-2016, Mexico).
The MIR and COC were dissolved and diluted in a sterile saline solution (0.9% NaCl, Sigma Aldrich). The solutions were freshly prepared before their intraperitoneal (i.p.) administration to the animals. The pH was adjusted to seven. During the experiments, the solutions were maintained at 4°C.
To determine if MIR can prevent the effects of cocaine, these were administered 30 minutes before cocaine or saline administration. The volume injected into the animals depended on their body weight (BW) in kilograms (BW (kg)/1ml).
2.2.1 Dose selection
The determination of the optimal dose of cocaine was based on previous studies. They reported that 10 mg/kg of cocaine induces a robust increase in locomotor activity and behavioral sensitization (32). This dose of cocaine does not cause seizures or lethality (32).
The optimal mirtazapine dose (30 mg/kg) was that of previous studies. They showed that ≥30 mg/kg mirtazapine does not affect spontaneous locomotor activity or produce sedation in rats, nor does it induce weight gain (46, 47). Preclinical and clinical trials have reported that 30 mg/kg of mirtazapine decreases cocaine-induced locomotor activity (27) and place preference (48).
2.3 Behavioral sensitization procedure
2.3.1 Apparatus
For each animal, we assessed locomotor activity in transparent Plexiglass activity chambers (50 x 50 x 30 cm) connected to a PC. Each chamber had a 16x16 photocell beam array located 3 cm from the floor surface to scan locomotor activity (OMNIALVA, Instruments, Mexico). Photobeam interruptions were automatically quantified with OABiomed software (1.1) and analyzed afterward. We defined locomotor activity as the continuous horizontal locomotor activity performed by a rat, which generates the simultaneous interruption of several photo beams (OMNIALVA, Mexico).
2.3.2 Procedure
We estimated spontaneous locomotor activity with a standard protocol (27). The animals were habituated to the activity chambers in three 30-minute sessions and were randomly assigned to different experimental procedures.
2.4 Dopamine and serotonin determination
Dopamine was determined with an HPLC standard protocol (49).
2.4.1 Tissue preparation
The animals were decapitated after treatment administration. The brain was rapidly removed, and the striatum containing the NAcc shell, prefrontal cortex (PFC), and VTA were dissected using blunt-tip curved microdissecting forceps on ice. The dissected tissue was placed into cryovials and then submerged in isopentane for snap freezing. The cryovials were placed on dry ice and then stored at -80°C. We analyzed the samples using high-pressure liquid chromatography (HPLC) and electrochemical detection.
2.4.2 Tissue homogenate preparation
Immediately before HPLC, the tissue was removed from the freezer, weighed, and homogenized. We performed homogenization using 400 µl of a solution containing 5% ascorbic acid, 200 mM sodium phosphate, 2.5 mM L-cysteine, 2.5 mM EDTA, and a Tekmar homogenizer for 20 seconds. Proteins were precipitated by adding 100 µl of 0.4 M perchloric acid followed by incubation at 20°C for 20 min. We collected supernatants containing DA after centrifugation at 12,000 rpm for 10 min (4°C). The samples were placed on ice and processed as soon as possible to prevent degradation. A portion of the supernatant (50 µl) was extracted and analyzed by HPLC to determine the DA concentration.
2.4.3 HPLC
Dopamine, serotonin and their metabolites (DOPAC-3,4-dihydroxyphenylacetic acid, HVA-Homo vanillic acid and HIIAA-5-hydroxyindoleacetic acid) concentrations were determined by reverse-phase HPLC (RP-HPLC) in a system equipped with two PU-2089 pumps (Jasco, Inc), a degasser (Jasco, Inc), an As-2057 autosampler (Jasco, Inc), and an XL-3120fp fluorescence detector (Jasco, Inc). Millenium 32 software (Waters™) controlled the instruments. A Jupiter C18 column (300 Å, 5 μ, 4.6 × 250 mm, Phenomenex®) was used at 30°C. We performed column equilibration with 0.1% trifluoroacetic acid as mobile phase A (MPA). As mobile phase B (MPB), we used a linear gradient from 0.1% trifluoroacetic acid in acetonitrile up to 20% MPB within 10 minutes (from min 5 to min 15). Then, 20% MPB was maintained up to min 20, with a flow rate of 0.8 ml/min.
The fluorescence detector was set at 280/315 nm excitation/emission, 32 attenuations, with the gain at 100 and a response time of 20 s. The sample injection volume was 50 μl.
2.5 Histology and immunohistochemistry
Rats were anesthetized with an overdose of pentobarbital sodium (Sedal-Vet, 65 mg/ml) and were perfused transcardially with ∼250 ml of 0.9% saline followed by 250 ml of 4% paraformaldehyde, 1.4% lysine, and 0.2% sodium m-periodate (PLP) fixative in PBS (0.1 M, pH 7.2). Brains were removed; postfixed for 1 h in PLP; and cryoprotected in 10, 20, and 30% sucrose for 24 h. Brains were frozen and cut at -18°C in horizontal sections of 40 μm to obtain complete slides of the brain. We serially collected sections in four sets.
One set was stained with cresyl violet acetate (Nissl), and a second set was processed for immunohistochemistry for c-fos. The sections were incubated for 72 h at 4°C in the primary antibody (rabbit anti-Fos; CAT SC-52, Santa Cruz) diluted 1: 2,500 in PBS, 1% goat serum, and 0.3% Triton X-100 (PBSGT). Tissue was then incubated in biotinylated secondary antibody (goat anti-rabbit; CAT PK-61–01, Vector Laboratories) diluted 1:200 in PBSGT for 2 h at room temperature, followed by incubation in an avidin-biotin complex (0.9% avidin and 0.9% biotin solutions; CAT PK-61–01, Vector Laboratories) in PBSGT for 2 h at room temperature. The tissue was then reacted in diaminobenzidine (0.5 mg/ml, in Trizma buffer 7.2) with hydrogen peroxide (35 μl, 30% H2O2). Between each step, the tissue was rinsed three times for 10 minutes in PBS. The tissue was mounted on gelatin-coated slides, and the label was intensified with osmium tetroxide 0.1% for 30 s (Baker Analyzed), dehydrated with alcohol, cleared with xylene, and placed under a coverslip with Permount.
2.5.1 Cell count
To quantify c-fos expression in the mesocorticolimbic dopaminergic system, four representative sections were selected under the stereotaxic atlas from (50). A first ventral section (interaural 11.70 mm) was selected to quantify c-fos-IR in the infralimbic cortex (IL). A second section (interaural 10.00 mm) contained the nucleus accumbens shell (AcbSh) and core (AcbC). A third section (interaural 3.70 mm) was used to sample the ventral tegmental area (VTA).
Images of the corresponding Nissl sections were obtained to identify and define the area for each nucleus. Images of the immunohistochemical preparation were obtained using a computerized image analysis system (Leica, Qwin Image Analyzer Imaging Research) attached to a Leica DM500 light microscope (BHT). For large nuclei, such as the AcbSh, AcbC, and VTA, the number of IR-c-fos cells was counted from photographs of 6 brain slices per rat from the 6–10 brain slices that comprise its rostro caudal extent. For smaller nuclei, such as the IL, it was sufficient to select 4 slices per rat. A grid of 20 × 20, 400-μm2 squares was superimposed onto the center of each nucleus, and only c-fos-IR cells on the left side of each section were manually counted at a 10× magnification. To minimize the number of false positives, background optical density (OD) was established in a nearby region lacking c-fos-IR. When the observer marked a c-fos-IR cell, the program showed its OD, and stained cells that reached or surpassed three times the background OD were positive and were counted. In contrast, cells under this staining threshold were not considered. The examiner who performed all counts was not aware of the treatment received by the individual animals.
2.6 Experimental procedures
The study used 128 male Wistar rats in two experiments. For Experiment 1 we used 96 animals in 4 groups (n = 8); and for Experiment 2, we used 32 animals in 4 groups (n = 8). Each experimental group received a different pharmacological treatment.
2.6.1 Experiment 1
To determine the effect of mirtazapine on the cocaine-induced increase in dopamine levels, this experiment was divided into four experimental phases. Phase I, or the cocaine-induction phase, lasted 10 days. The drug-withdrawal phase lasted 30 days. Phase III, or the cocaine-expression phase, lasted 10 days. Phase IV, or the sacrifice phase, lasted 1 day (Figure 1A).
Figure 1. Mirtazapine reduces dopamine and serotonin levels. Experimental timeline. (A). MIR (30 mg/kg i.p.) administered for 30 days during drug withdrawal attenuates cocaine-induced locomotor, and cocaine sensitization (B, C). Mean locomotor activity (± S.E.M.) by group (n = 8 animals per group) *p < 0.01 significant effects of cocaine treatment on locomotor activity compared to the SAL + SAL groups. **p < 0.01 significant effects of different multitarget drugs on locomotor activity compared to the SAL + COC group, § p < 0.01 significant effects between the induction and expression phase, as determined by three-way ANOVA followed by Tukey’s tests. The dopamine and serotonin concentration (± S.E.M.) by group (n = 8 animals per group) in the striatum (D, G), ventral-tegmental area (E, H), and prefrontal cortex (F, I). *p < 0.01 significant effects of cocaine treatment on dopamine or serotonin levels compared to the SAL + SAL groups. **p < 0.01 significant effects of mirtazapine on dopamine or serotonin levels compared to the SAL + COC group. #p < 0.01 significant effects between the MIR + COC and MIR + SAL groups. $p < 0.01 significant effects of cocaine treatment on DOPAC levels compared to the SAL + SAL groups. £p < 0.01 significant effects of mirtazapine on DOPAC levels compared to the SAL + COC group. &p < 0.01 significant effects of cocaine treatment on HVA levels compared to the SAL + SAL groups. ¥p < 0.01 significant effects of cocaine treatment on HIIAA levels compared to the SAL + SAL groups. §p < 0.01 significant effects of mirtazapine on HIIAA levels compared to the SAL + COC group, as determined by four-way ANOVA followed by Tukey’s tests.
The SAL + SAL and SAL + MIR groups received saline, 30 minutes before saline daily administration, during the induction phase. During the drug-withdrawal, expression, and sacrifice phases received mirtazapine (30 mg/Kg), 30 minutes before saline administration.
The SAL + COC group received saline, 30 minutes before cocaine daily administration, during the induction, expression, and sacrifice phases. During the drug-withdrawal phase, cocaine was withdrawn, and the group received saline 30 minutes before saline administration.
The MIR + COC groups received cocaine daily during the induction phase. During the drug-withdrawal, expression, and sacrifice phases, the rats received mirtazapine, 30 minutes before the administration of saline or cocaine (10 mg/kg, i.p.), respectively. After each administration, the animals were immediately placed into the activity chambers, and the locomotor activity of each animal was recorded for 30 minutes.
In the sacrifice phase, after each administration, the animals were sacrificed at 10, 20, or 30 minutes after treatment (Figure 1A).
2.6.2 Experiment 2
This experiment was performed to determine the effect of mirtazapine on cocaine-induced Fos protein expression. For this, Experiment 2 was divided into four phases. Phase I, or the cocaine-induction phase, lasted 10 days. Phase II, or the drug-withdrawal phase, lasted 30 days. The cocaine-expression phase lasted 10 days. Phase IV, or the sacrifice phase, lasted 1 day (Figure 2A).
Figure 2. Mirtazapine reduces the number of cells immunoreactive to c-fos. Experimental timeline. (A). MIR (30 mg/kg i.p.) administered for 30 days during drug withdrawal attenuates cocaine-induced locomotor, and cocaine sensitization (B, C). Mean locomotor activity (± S.E.M.) by group (n = 8 animals per group) *p < 0.01 significant effects of cocaine treatment on locomotor activity compared to the SAL + SAL groups. **p < 0.01 significant effects of different multitarget drugs on locomotor activity compared to the SAL + COC group, § p < 0.01 significant effects between the induction and expression phase, as determined by three-way ANOVA followed by Tukey’s tests. The number of cells immunoreactive to c-fos (± S.E.M.) by group (n = 8 animals per group) in the infralimbic cortex (D), AcbC (E), AcbSh (F), and ventral-tegmental area (G). *p < 0.01 significant effects of cocaine treatment on the number of cells immunoreactive to c-fos compared to the SAL + SAL groups. **p < 0.01 significant effects of mirtazapine on the number of cells immunoreactive to c-fos compared to the SAL + COC group. #p < 0.01 significant effects between the MIR + COC and MIR + SAL groups, as determined by two-way ANOVA followed by Tukey’s tests.
The SAL+ SAL and SAL + MIR groups received saline solution (9% NaCl, i.p.), 30 minutes before saline daily administration, during the induction phase. During the drug-withdrawal, expression, and sacrifice phases received mirtazapine (30 mg/Kg), 30 minutes before saline administration.
The SAL + COC group received cocaine (10 mg/kg, i.p.) daily during induction and expression. During the cocaine-withdrawal phase, cocaine was withdrawn, and the groups received daily saline only.
The MIR + COC group received cocaine daily during the induction phase. During drug withdrawal and expression, the rats received mirtazapine 30 minutes before administration of either saline or cocaine (10 mg/kg, i.p.).
During the sacrifice phase, the SAL + SAL, SAL + MIR, SAL + COC and MIR + COC groups received saline (9% NaCl, i.p.) or mirtazapine (30 mg/kg, i.p.), 30 minutes before saline or cocaine (10 mg/kg, i.p.), respectively. After each administration, the animals were sacrificed 45 minutes after treatment. (Figure 2A). The intracellular cascade of events to produce peak levels of the protein c-fos is estimated to take ∼45 min (Wang et al., 1996).
2.7 Statistical analysis
Data are expressed as the means ± S.E.M. Locomotor activity was measured by counting beam breaks during the testing session. For the graphic representation, in
In experiments 1 and 2, to determine the effect of each of the mirtazapine on cocaine locomotor sensitization, the mean cocaine-induced locomotor activity of the last 10 days of the induction phase was compared versus the mean locomotor activity of the first 10 days of the expression phase (comparison between phases). The results for locomotor activity in each group during the expression phase were analyzed with a three-way analysis of variance (ANOVA) with treatments (saline, or mirtazapine), groups (saline or cocaine), and phase (induction and expression) as the between-subjects factors. If the interaction yielded a significant F value, a post-hoc analysis of differences was performed between groups followed by an additional Tukey’s test.
For Experiment 1, we used a four-way ANOVA with groups, treatments, time (10, 20, 30 minutes), and metabolites as the between-subject factors. For Experiment 2, the study used a two-way analysis of variance (ANOVA) with treatments (saline, or mirtazapine) and groups (saline or cocaine) as the between-subject factors, followed by a post-hoc analysis. When there was a significant F value in the interaction, a Tukey test of differences between groups was performed. Statistical analysis was performed with SPSS version 21 (IBM, 2021). The statistical significance level was set at p < 0.05.
3 Results
3.1 Locomotor activity
As shown in Figures 1B, C, 2B, C, cocaine significantly increased locomotor activity during expression (Experiment 1; three-way ANOVA; in the group X treatment X phase interaction, F (1, 64) = 269.040 p < 0.0001 experiments 2; three-way ANOVA; in the group X treatment X phase interaction, F (1, 64) = 271.538 p < 0.0001), compared to the SAL + SAL (p < 0.0001) and the MIR + SAL (p < 0.0001) groups. In contrast, in rats that had previously received a dose of mirtazapine during cocaine withdrawal, cocaine administration did not significantly increase locomotor activity, as occurred in animals in the SAL + COC group. The Tukey’s test found differences in cocaine-induced locomotor activity when comparing the MIR + COC group to the SAL + SAL (p < 0.002), the MIR + SAL (p < 0.002), and the SAL + COC (p < 0.0001) groups (Figures 1B, 2B).
When the differences between the induction phase and the expression phase (locomotor sensitization) were compared, Tukey’s test found significant differences in the cocaine-induced locomotor activity shown during the induction phase compared to that shown in the expression phase in the SAL + COC (p < 0.001) group. Additionally, the post-hoc test found a decrease in cocaine-induced locomotor activity during the induction phase compared to that shown during the expression phase in the MIR + COC (p < 0.001) groups. This suggests that the treatment decreased the expression of cocaine locomotor sensitization.
3.2 Experiment 1
3.2.1 Dopamine
Figures 1D–F shows the dopamine levels in the striatum (four-way ANOVA; in the groups, treatments, time X metabolite interaction, F (4, 288) = 1307.358 p < 0.0001), PFC (four-way ANOVA; in the groups, treatments, time X metabolite interaction, F (4, 288) = 6623.183 p < 0.0001) and VTA (four-way ANOVA; in the groups, treatments, time X metabolite interaction, F (4, 288) = 134.799 p < 0.0001) at 10, 20 or 30 minutes after the administration of the treatments.
The statistical analysis found differences in the levels of dopamine shown by the animals of the SAL + COC group compared to those shown by the SAL + SAL (p < 0.0001) and MIR + SAL (p < 0.0001) groups at 10, 20, or 30 minutes after administration in each of the brain structures analyzed (Figures 1D–F).
Tukey’s test found significant differences in the levels of dopamine in the striatum, PFC, and VTA between the MIR + COC group and the SAL + COC (p < 0.0001) group, at 10, 20, or 30 minutes after administration. However, there were no differences between the MIR + COC and MIR + SAL groups (p = 0.81) in the VTA.
Furthermore, the post-hoc test found significant differences in the levels of DOPAC in the striatum, VTA, and PFC showed by the SAL + SAL group concerning the levels shown by the MIR + SAL (p < 0.002) and MIR + COC groups (p < 0.002) at 10, 20, or 30 minutes after administration. In addition, Tukey’s test revealed differences between the SAL + COC group concerning the MIR + SAL (p < 0.002) and MIR + COC (p < 0.002) groups in the striatum and PFC, but the post-hoc analysis did not find differences between the SAL + COC group concerning the MIR + SAL (p = 0.64) and MIR + COC (p = 0.71) groups in the VTA at 10, 20, or 30 minutes after administration.
Regarding HVA levels, Tukey’s test found differences between the SAL + COC group concerning the MIR + SAL (p < 0.002) and MIR + COC (p < 0.002) groups in the striatum and PFC, but it did not find differences between the SAL + COC group concerning the MIR + SAL (p = 0.59) and MIR + COC (p = 0.78) groups in the VTA at 10, 20, or 30 minutes after administration.
3.2.2 Serotonin
Figures 1G–I shows the serotonin levels in the striatum (four-way ANOVA; in the groups, treatments, time X metabolite interaction, F (2, 191) = 756.174 p < 0.0001), PFC (four-way ANOVA; in the groups, treatments, time X metabolite interaction, F (2, 191) = 26224.651 p < 0.0001) and VTA (four-way ANOVA; in the groups, treatments, time X metabolite interaction, F (2, 191) = 29806.773 p < 0.0001) at 10, 20 or 30 minutes after the administration of the treatments.
The statistical analysis found differences in the levels of serotonin shown by the animals of the SAL + COC group compared to those shown by the SAL + SAL (p < 0.0001) and MIR + SAL (p < 0.0001) groups at 10, 20, or 30 minutes after administration in each of the brain structures analyzed (Figures 1G–I).
Tukey’s test found significant differences in the levels of serotonin in the striatum, PFC, and VTA between the MIR + COC group and the SAL + COC (p < 0.0001) group, at 10, 20, or 30 minutes after administration. Furthermore, the post-hoc test found differences between the MIR + SAL and MIR + COC (p < 0.002) groups in the levels of serotonin in the striatum and VTA. However, he found no differences (p = 0.94) between these groups in the PFC at 10, 20, or 30 minutes after administration.
However, there were no differences between the SAL + SAL and MIR + SAL groups (p = 0.97) in the striatum, PFC, and VTA, at 10, 20, or 30 minutes after administration.
Additionally, Tukey’s test revealed differences in the levels of HIIAA in the striatum, PFC, and VTA shown by the SAL + SAL group compared to those shown by the SAL + COC (p < 0.0002) and MIR + COC (p < 0.0002) groups. But no differences were found concerning the MIR + SAL (p = 0.92) group, at 10, 20, or 30 minutes after administration. Furthermore, the statistical test revealed differences in the levels of HIIAA in the PFC, and VTA shown by the SAL + COC group compared to the MIR + SAL (p < 0.002) group but did not find differences concerning the MIR + COC (p = 0.96) group, at 10, 20, or 30 minutes after administration.
In the striatum, Tukey’s test revealed differences in HIIAA levels, at 10, 20, or 30 minutes after administration, between the SAL + COC and MIR + COC (p < 0.002) groups. However, the post-hoc test did not find differences concerning the MIR + SAL (p = 0.87) group.
3.3 Experiment 2
Two-way ANOVA found significant differences in the number of c-fos-IR cells in the IL (two-way ANOVA; in the groups by treatment interaction, F (1, 31) = 3245.773 p < 0.0001), AcbSh (two-way ANOVA; in the groups by treatment interaction, F (1. 31) = 1582.824 p < 0.0001), AcbC (two-way ANOVA; in the groups by treatment interaction, F (1. 31) = 1968.75 p < 0.0001), and VTA (two-way ANOVA; in the groups by treatment interaction, F (1. 31) = 653.722 p < 0.0001).
Tukey’s test found differences in the number of c-fos-IR cells as shown by the animals of the SAL + COC group compared to those shown by the SAL + SAL (p < 0.0001), MIR + SAL (p < 0.0001), and MIR + SAL (p < 0.0001) groups in each of the brain nuclei analyzed (Figures 2D–G, 3).
Figure 3. Representative photomicrographs of Fos protein expression in the IL, AcbS, AcbC, and VTA of rats from all experimental groups at 20× magnification, where Fos protein expression was visible as dark ovals (highlighted by arrows). Scale bar = 100 μm.
The post-hoc test found significant differences in the number of c-fos-IR cells in the IL, AcbSh, AcbC, and VTA between the MIR + COC group and the MIR + SAL (p < 0.0001) group (Figures 2D–G, 3).
4 Discussion
Pioneering studies demonstrated a cocaine-induced increase in dopamine and serotonin release in the ventral striatum, VTA, and PFC (4, 5, 51–57). The results of this study are in line with this evidence, where cocaine administration generated an increase in dopamine and serotonin levels in the ventral striatum, VTA, and PFC.
On the other hand, several studies have revealed that cocaine-induced behavioral sensitization is related to a rise in dopamine levels (58, 59), which reaches its maximum level at 20–40 minutes of injection and returns to baseline levels 80 minutes after injection (60, 61). These results are consistent with what was observed in this study, where the locomotor activity induced by cocaine is associated with an increase in dopamine levels in the Acb, VTA, and PFC.
However, the magnitude of the cocaine-induced increase in dopamine levels differs from that reported by other studies (4, 62–65). Various studies have shown that cocaine-induced stimulant actions involve cocaine-induced joint alteration of various neurotransmission systems (66, 67). Cocaine acts on the neuronal membrane monoamine transporters NET, DAT, and SERT to inhibit the reuptake of neurotransmitters. However, the psychostimulant effects of cocaine may have additional effects involving pre- and postsynaptic/junctional receptors for norepinephrine, serotonin, and other receptors. As a result, cocaine’s psychostimulant effects can be greatly increased. Pioneering studies have reported that cocaine increases the levels of 5-HT and NE (54–57) in the mesolimbic-cortical system. These studies have shown that 5-HT and NE modulate cocaine-induced dopamine levels, through their action on 5-HT2, 5-HT3, and α1NE receptors located on dopaminergic neurons (68, 69). Thus, activation of these receptors enhances the increase in cocaine-induced dopamine levels in the ventral striatum and PFC (68, 70, 71). On the other hand, other studies have shown that cocaine induces an increase in the levels of glutamate in the prefrontal cortex and in the ventral tegmental area (71, 72), which, through its action on mGlu2/3/5 receptors, modulates dopamine levels in the ventral striatum (73–76). Thus, the joint action of these three neurotransmission systems and probably others (cannabinoids) on the dopaminergic neurons of the ventral striatum and the PFC, could explain the increase in dopamine levels reported in this study.
Other studies have shown that mirtazapine alters dopamine levels in freely moving rats via the blockade of α2-adrenergic receptors and agonism of postsynaptic 5-HT1A receptors (77–80) in the PFC. These studies additionally reported that mirtazapine could not increase intracellular dopamine levels in the ventral striatum or VTA. These results are consistent with what was found in this study, where mirtazapine only increased dopamine levels in the PFC.
Furthermore, in this study we found that mirtazapine slightly affected DOPAC and HVA levels in the striatum and VTA; but in the PFC, mirtazapine increased the levels of DOPAC and HVA. These results agree with previous works that show that mirtazapine did not alter the levels of DOPAC and HVA in the striatum but increased them in the PFC (78, 81).
Studies in rodents reported that the administration of mirtazapine did not generate an increase in 5-HT levels in PFC and striatum (77, 79). Our results are in line with these studies. Where the administration of mirtazapine did not increase the release of 5-HT in the striatum, VTA, and PFC.
We found that mirtazapine dosing significantly decreased cocaine-induced ex vivo relative DA and 5-HT content in the ventral striatum, VTA, and PFC. We have not found similar results in the literature. However, individual dosing of serotonin 5-HT2A or 5-HT3 receptor antagonists have been reported (67, 82–85) or α2 NE and serotonin 5-HT1A receptor agonists (54, 86, 87) decreased cocaine-induced dopamine levels. These results suggest that the mirtazapine-induced decrease in cocaine-induced DA and 5-HT levels is probably due to the action of mirtazapine on pre- and post-synaptic 5-HT1A, 5-HT2A, and 5-HT3 receptors located on dopaminergic and serotonergic neurons.
Pioneering studies showed that cocaine induces an increase in immunoreactivity to c-fos in the ventral striatum (88, 89). Similar results were found in this study, where 10 mg/kg cocaine significantly increased the number of c-fos immunoreactive cells in the ventral striatum, VTA, and PFC.
In contrast, mirtazapine dosing significantly decreased cocaine-induced c-fos expression. To our knowledge, similar results have not been reported. However, the blockade of serotonin 5-HT2A or 5-HT3 receptors and activation of serotonin 5-HT2C receptors reduced cocaine-induced Fos protein expression in the striatum (82, 90–92).
Some studies have reported that the cocaine-induced increase in dopamine levels is related to the increase in immunoreactivity to c-fos in the striatum (11, 12, 91). These studies showed that cocaine-induced Fos protein expression depends on differential activation of dopamine D1 and D2 receptors (11, 12, 93).
Thus, like the increase in cocaine-induced locomotor activity and the increase in cocaine-induced Fos protein expression, it is related to the increase in cocaine-induced dopamine levels and depends on the differential activation of dopamine D1 and D2 receptors in the striatum. Other studies have shown that mirtazapine produced altered expression in the ratio of D1/D2-like dopamine receptors in the NAcc, which could lead to a decrease in dopamine levels and subsequent attenuation of cocaine-induced locomotor sensitization and c-fos protein expression (94, 95).
In summary, 1) cocaine increases the levels of DA (4, 5, 51–53), 5-HT (54–57), and the expression of the c-fos protein in the mesolimbic-cortical system. 2) the activation of 5-HT2, 5-HT3, and α1 NE receptors located on dopaminergic neurons enhances the increase in cocaine-induced dopamine levels (68–71). 3) Serotonin 5-HT2A or 5-HT3 receptor antagonists (67, 82–85) or α2 NE and serotonin 5-HT1A receptor agonists decreased cocaine-induced dopamine levels (54, 86, 87) and Fos protein expression in the striatum (82, 90–92). 4) Mirtazapine, carries out its therapeutic effects through antagonism of the α2 NE receptor, and block of the 5HT2A/C and 5HT3 and histamine 1 (H1R) receptors (29). Additionally, mirtazapine can also act as an inverse agonist of the 5-HT2C receptor and indirectly as an agonist of the 5-HT1A receptor (80, 96). Thus, it is likely that mirtazapine, by simultaneously antagonizing 5-HT2A and 5-HT3 receptors and activating 5-HT1A receptors, decreased cocaine-induced DA and 5-HT levels, the activation of dopamine D1 and D2 receptors, and the subsequent expression of the Fos protein in the mesolimbic-cortical system.
5 Conclusions
The cocaine-induced locomotor activity depends mainly on the increase in extracellular levels of dopamine and on the subsequent activation of different neuronal circuits (4, 88). Additionally, the effects on behavior (expression of locomotor sensitization) and synaptic reorganization produced by chronic cocaine exposure depend on the dopamine-dependent Fos protein expression (22, 23). On the other hand, previously we demonstrated that the daily dosage of mirtazapine during withdrawal decreased the induction and expression of locomotor sensitization to methamphetamine, cocaine, and nicotine (27, 32, 33, 39) in male rats. Additionally, in this study, we showed for the first time that mirtazapine significantly attenuated the cocaine-induced increase in dopamine release and Fos protein expression. Thus, these data suggest that mirtazapine probably, through its mechanism of action, decreased the cocaine-induced increase in dopamine levels, which resulted in a decrease in the activation of dopamine D1 receptors and the subsequent cocaine-induced Fos protein expression. This could prevent the consolidation of changes in behavior (decreased mirtazapine-dependent expression of cocaine locomotor sensitization) and in the cocaine-induced reorganization of neuronal circuits. It would explain the mirtazapine-induced effects on cocaine behavioral sensitization. Thus, these data together could support its possible use for the treatment of patients with CUD.
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.
Ethics statement
The animal study was approved by The Institutional Animal Care- and Bioethics Committee approved the procedures (CEI/C/IC092020/2006). The study was conducted in accordance with the local legislation and institutional requirements.
Author contributions
AS-J: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft. SB-M: Investigation, Methodology, Project administration, Supervision, Writing – original draft.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was carried out thanks to grants INP-2000-2040 and CI-IC092020.2.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1428730/full#supplementary-material
References
1. Shorter D, Kosten TR. Novel pharmacotherapeutic treatments for cocaine addiction. BMC Med. (2011) 9:119. doi: 10.1186/1741-7015-9-119
2. McLellan AT. Substance Misuse, and Substance Use Disorders: Why do they Matter in Healthcare? Trans Am Clin Climatol Assoc. (2017) 128:112–30.
3. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. (1996) 379:606–12. doi: 10.1038/379606a0
4. Kalivas PW, Duffy P. Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse. (1990) 5:48–58. doi: 10.1002/syn.890050104
5. Moghaddam B, Bunney BS. Differential effect of cocaine on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens: comparison to amphetamine. Synapse. (1989) 4:156–61. doi: 10.1002/syn.890040209
6. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. (1998) 78:189–225. doi: 10.1152/physrev.1998.78.1.189
7. Caine SB, Thomsen M, Gabriel KI, Berkowitz JS, Gold LH, Koob GF, et al. Lack of self-administration of cocaine in dopamine D1 receptor knock-out mice. J Neurosci. (2007) 27:13140–50. doi: 10.1523/JNEUROSCI.2284-07.2007
8. Xu M, Guo Y, Vorhees CV, Zhang J. Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor. Brain Res. (2000) 852:198–207. doi: 10.1016/S0006-8993(99)02258-1
9. Xu M, Zhang J. Molecular genetic probing of dopamine receptors in drug addiction. Curr Opin Drug Discov Devel. (2004) 7:703–8.
10. Hope B, Kosofsky B, Hyman SE, Nestler EJ. Regulation of immediate early gene expression and AP-1 binding in the rat nucleus accumbens by chronic cocaine. Proc Natl Acad Sci USA. (1992) 89:5764–8. doi: 10.1073/pnas.89.13.5764
11. Robertson GS, Jian M. D1 and D2 dopamine receptors differentially increase Fos-like immunoreactivity in accumbal projections to the ventral pallidum and midbrain. Neuroscience. (1995) 64:1019–34. doi: 10.1016/0306-4522(94)00426-6
12. Young ST, Porrino LJ, Iadarola MJ. Cocaine induces striatal c-fos-immunoreactive proteins via dopaminergic D1 receptors. Proc Natl Acad Sci USA. (1991) 88:1291–5. doi: 10.1073/pnas.88.4.1291
13. Morgan JI, Cohen DR, Hempstead JL, Curran T. Mapping patterns of c-fos expression in the central nervous system after seizure. Science. (1987) 237:192–7. doi: 10.1126/science.3037702
14. Morgan JI, Curran T. Stimulus-transcription coupling in neurons: Role of cellular immediate-early genes. Trends Neurosci. (1989) 12:459–62. doi: 10.1016/0166-2236(89)90096-9
15. Morgan JI, Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci. (1991) 14:421–51. doi: 10.1146/annurev.ne.14.030191.002225
16. Duclot F, Kabbaj M. The role of early growth response 1 (EGR1) in brain plasticity and neuropsychiatric disorders. Front Behav Neurosci. (2017) 6:11. doi: 10.3389/fnbeh.2017.00035
17. Lanahan A, Worley P. Immediate-early genes and synaptic function. Neurobiol Learn Memory. (1998) 70:37–43. doi: 10.1006/nlme.1998.3836
18. Okuno H. Regulation and function of immediate-early genes in the brain: beyond neuronal activity markers. Neurosci Res. (2011) 69:175–86. doi: 10.1016/j.neures.2010.12.007
19. Kim S, Kim H, Um JW. Synapse development organized by neuronal activity-regulated immediate-early genes. Exp Mol Med. (2018) 50:1–7. doi: 10.1038/s12276-018-0025-1
20. Salery M, Godino A, Nestler EJ. Drug-activated cells: From immediate early genes to neuronal ensembles in addiction. Adv Pharmacol. (2021) 90:173–216. doi: 10.1016/bs.apha.2020.09.006
21. Xu M. c-Fos is an intracellular regulator of cocaine-induced long-term changes. Ann N Y Acad Sci. (2008) 1139:1–9. doi: 10.1196/annals.1432.049
22. Zhang D, Zhang L, Tang Y, Zhang Q, Lou D, Sharp FR, et al. Gene expression changes induced by repeated cocaine administration through the dopamine D1 receptors. Neuropsychopharmacology. (2005) 30:1443–54. doi: 10.1038/sj.npp.1300680
23. Zhang J, Zhang L, Jiao H, Zhang Q, Zhang D, Lou D, et al. c-Fos facilitates the acquisition and extinction of cocaine-induced persistent changes. J Neurosci. (2006) 26:13287–96. doi: 10.1523/JNEUROSCI.3795-06.2006
24. Herdegen T, Leah JD. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Brain Res Rev. (1998) 28:370–490. doi: 10.1016/S0165-0173(98)00018-6
25. Lucibello FC, Lowag C, Neuberg M, Müller R. trans-repression of the mouse c-fos promoter: a novel mechanism of Fos-mediated trans-regulation. Cell. (1989) 59:999–1007. doi: 10.1016/0092-8674(89)90756-3
26. Nanni-Alvarado R, Marín-Navarrete R, González M, Lima C, Barbosa-Méndez S, Salazar-Juarez A. Effect of mirtazapine on craving in cocaine depended patients. Int J Ment Health Addict. (2021) 20:2770–86. doi: 10.1007/s11469-021-00547-6
27. Salazar-Juárez A, Barbosa-Méndez S, Jurado N, Hernandez-Miramontes R, Anton B. Mirtazapine prevents induction and expression of cocaine-induced behavioral sensitization in rats. Prog Neuropsychopharmacol Biol Psychiatry. (2016) 68:15–24. doi: 10.1016/j.pnpbp.2016.02.010
28. Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. (2009) 23:427–52. doi: 10.2165/00023210-200923050-00006
29. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. (1996) 57 Suppl 4:19–25.
30. Barbosa-Méndez S, Jurado N, Matus-Ortega M, Martiñon-Gutierrez S, Heinze G. Mirtazapine attenuates the expression of nicotine-induced locomotor sensitization in rats. Eur J Pharmacol. (2017) 812:28–37. doi: 10.1016/j.ejphar.2017.06.028
31. Barbosa-Méndez S, Leff P, Arías-Caballero A, Hernandez-Miramontes R, Heinze G. Mirtazapine attenuates cocaine seeking in rats. J Psychiatr Res. (2017) 92:38–46. doi: 10.1016/j.jpsychires.2017.03.021
32. Barbosa-Méndez S, Matus-Ortega M, Flores-Zamora A, Jurado N, Salazar-Juárez A. Dose- and time-dependent effects of mirtazapine on the expression of cocaine-induced behavioral sensitization in rats. Psychiatry Res. (2017) 254:301–10. doi: 10.1016/j.psychres.2017.05.006
33. Barbosa-Méndez S, Salazar-Juárez A. Mirtazapine attenuates nicotine-seeking behavior in rats. J Psychopharmacol. (2018) 32:1010–7. doi: 10.1177/0269881118764991
34. Barbosa-Méndez S, Becerril-Villanueva E, Ponce-Regalado MD, Salazar-Juárez A. Mirtazapine: Multi-target strategies for treating substance use disorder and depression. In: The neuroscience of depression: features, diagnosis, and treatment. London United Kingdom: Elsevier-Academic Press. (2021) p. 401–10.
35. Kang L, Wang D, Li B, Hu M, Zhang P, Li J. Mirtazapine, a noradrenergic and specific serotonergic antidepressant, attenuates morphine dependence and withdrawal in Sprague-Dawley rats. Am J Drug Alcohol Abuse. (2008) 34:541–52. doi: 10.1080/00952990802183921
36. McDaid J, Tedford CE, Mackie AR, Dallimore JE, Mickiewicz AL, Shen F, et al. Nullifying drug-induced sensitization: behavioral and electrophysiological evaluations of dopaminergic and serotonergic ligands in methamphetamine-sensitized rats. Drug Alcohol Depend. (2007) 86:55–66. doi: 10.1016/j.drugalcdep.2006.05.014
37. Voigt RM, Napier TC. Context-dependent effects of a single administration of mirtazapine on the expression of methamphetamine-induced conditioned place preference. Front Behav Neurosci. (2012) 13:92. doi: 10.3389/fnbeh.2011.00092
38. Graves SM, Napier TC. Mirtazapine alters cue-associated methamphetamine seeking in rats. Biol Psychiatry. (2011) 69:275–81. doi: 10.1016/j.biopsych.2010.09.032
39. Graves SM, Napier TC. SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in rats. BMC Neurosci. (2012) 14:13:65. doi: 10.1186/1471-2202-13-65
40. Barbosa-Méndez S, Salazar-Juárez A. Mirtazapine attenuates anxiety- and depression-like behaviors in rats during cocaine withdrawal. J Psychopharmacol. (2019) 33:589–605. doi: 10.1177/0269881119840521
41. Afshar M, Knapp CM, Sarid-Segal O, Devine E, Colaneri LS, Tozier L, et al. The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression. Am J Drug Alcohol Abuse. (2012) 38:181–6. doi: 10.3109/00952990.2011.644002
42. Brunette MF, Akerman SC, Dawson R, O'Keefe CD, Green AI. An open-label pilot study of quetiapine plus mirtazapine for heavy drinkers with alcohol use disorder. Alcohol. (2016) 53:45–50. doi: 10.1016/j.alcohol.2016.02.006
43. Colfax GN, Santos GM, Das M, Santos DM, Matheson T, Gasper J, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. (2011) 68:1168–75. doi: 10.1001/archgenpsychiatry.2011.124
44. Chandrasekaran PK. Employing mirtazapine to aid benzodiazepine withdrawal. Singapore Med J. (2008) 49:e166–7.
45. Liappas J, Paparrigopoulos T, Malitas P, Tzavellas E, Christodoulou G. Mirtazapine improves alcohol detoxification. J Psychopharmacol. (2004) 18:88–93. doi: 10.1177/0269881104040241
46. Bittolo T, Raminelli CA, Deiana C, Baj G, Vaghi V, Ferrazzo S, et al. Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice. Sci Rep. (2016) 6:19796. doi: 10.1038/srep19796
47. Salazar-Juárez A, Barbosa-Méndez S, Merino-Reyes P, Matus-Ortega M, Hernandez-Calderon J, Antón B. Chronic dosing with mirtazapine does not produce sedation in rats. Braz J Psychiatry. (2017) 39:228–36. doi: 10.1590/1516-4446-2016-2058
48. Barbosa-Méndez S, Matus-Ortega M, Jacinto-Gutiérrez S, Salazar-Juárez A. Mirtazapine impairs acquisition and reinstatement of cocaine-induced place preference in rats. Eur J Pharmacol. (2018) 820:183–90. doi: 10.1016/j.ejphar.2017.12.033
49. Becerril-Villanueva E, Ponce-Regalado MD, Pérez-Sánchez G, Salazar-Juárez A, Arreola R, Álvarez-Sánchez ME, et al. Chronic infection with Mycobacterium lepraemurium induces alterations in the hippocampus associated with memory loss. Sci Rep. (2018) 8:9063. doi: 10.1038/s41598-018-27352-x
50. Paxinos G, Watson CH. The rat brain in stereotaxic coordinates, 4th ed. USA: Academic Press, Inc. (1998).
51. Hurd YL, Ungerstedt U. Cocaine: an in vivo microdialysis evaluation of its acute action on dopamine transmission in rat striatum. Synapse. (1989) 3:48–54. doi: 10.1002/syn.890030107
52. Reith ME, Li MY, Yan QS. Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacol (Berl). (1997) 134:309–17. doi: 10.1007/s002130050454
53. Sorg BA, Davidson DL, Kalivas PW, Prasad BM. Repeated daily cocaine alters subsequent cocaine-induced increase of extracellular dopamine in the medial prefrontal cortex. J Pharmacol Exp Ther. (1997) 281:54–61.
54. Devoto P, Flore G, Saba P, Cadeddu R, Gessa GL. Disulfiram stimulates dopamine release from noradrenergic terminals and potentiates cocaine-induced dopamine release in the prefrontal cortex. Psychopharmacol (Berl). (2012) 219:1153–64. doi: 10.1007/s00213-011-2447-5
55. Fletcher PJ, Grottick AJ, Higgins GA. Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology. (2002) 27:576–86. doi: 10.1016/S0893-133X(02)00342-1
56. Vanderschuren LJ, Beemster P, Schoffelmeer AN. On the role of noradrenaline in psychostimulant-induced psychomotor activity and sensitization. Psychopharmacol (Berl). (2003) 169:176–85. doi: 10.1007/s00213-003-1509-8
57. Drouin C, Darracq L, Trovero F, Blanc G, Glowinski J, Cotecchia S, et al. Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci. (2002) 22:2873–84. doi: 10.1523/JNEUROSCI.22-07-02873.2002
58. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA. (1988) 85:5274–8. doi: 10.1073/pnas.85.14.5274
59. Heidbreder CA, Thompson AC, Shippenberg TS. Role of extracellular dopamine in the initiation and long-term expression of behavioral sensitization to cocaine. J Pharmacol Exp Ther. (1996) 278:490–502.
60. Kalivas PW, Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. J Neurosci. (1993) 13:266–75. doi: 10.1523/JNEUROSCI.13-01-00266.1993
61. Kalivas PW, Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine. II Dopamine perikarya J Neurosci. (1993) 13:276–84. doi: 10.1523/JNEUROSCI.13-01-00276.1993
62. Kalivas PW, Duffy P, DuMars LA, Skinner C. Behavioral and neurochemical effects of acute and daily cocaine administration in rats. J Pharmacol Exp Ther. (1988) 245:485–92.
63. Kalivas PW, Duffy P. Effects of daily cocaine and morphine treatment on somatodendritic and terminal field dopamine release. J Neurochem. (1988) 50:498–504. doi: 10.1111/j.1471-4159.1988.tb03036.x
64. Kohler RJ, Perrine SA, Baker LE. Repeated exposure to 3,4-methylenedioxypyrovalerone and cocaine produces locomotor sensitization with minimal effects on brain monoamines. Neuropharmacology. (2018) 134:22–7. doi: 10.1016/j.neuropharm.2017.10.019
65. Müller CP, Homberg JR. The role of serotonin in drug use and addiction. Behav Brain Res. (2015) 277:146–92. doi: 10.1016/j.bbr.2014.04.007
66. Zaniewska M, Filip M, Przegalinski E. The involvement of norepinephrine in behaviors related to psychostimulant addiction. Curr Neuropharmacol. (2015) 13:407–18. doi: 10.2174/1570159X13666150121225659
67. Bubar MJ, McMahon LR, De Deurwaerdère P, Spampinato U, Cunningham KA. Selective serotonin reuptake inhibitors enhance cocaine-induced locomotor activity and dopamine release in the nucleus accumbens. Neuropharmacology. (2003) 44:342–53. doi: 10.1016/S0028-3908(02)00381-7
68. Howell LL, Cunningham KA. Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder. Pharmacol Rev. (2015) 67:176–97. doi: 10.1124/pr.114.009514
69. King GR, Xue Z, Calvi C, Ellinwood EH. 5-HT3 agonist-induced dopamine overflow during withdrawal from continuous or intermittent cocaine administration. Psychopharmacol (Berl). (1995) 117:458–65. doi: 10.1007/BF02246219
70. Yan Q, Reith ME, Yan S. Enhanced accumbal dopamine release following 5-HT(2A) receptor stimulation in rats pretreated with intermittent cocaine. Brain Res. (2000) 863:254–8. doi: 10.1016/S0006-8993(00)02080-1
71. Kalivas PW, Duffy P. Repeated cocaine administration alters extracellular glutamate in the ventral tegmental area. J Neurochem. (1998) 70:1497–502. doi: 10.1046/j.1471-4159.1998.70041497.x
72. Reid MS, Berger SP. Evidence for sensitization of cocaine-induced nucleus accumbens glutamate release. Neuroreport. (1996) 7:1325–9. doi: 10.1097/00001756-199605170-00022
73. Li X, Peng XQ, Jordan CJ, Li J, Bi GH, He Y, et al. mGluR5 antagonism inhibits cocaine reinforcement and relapse by elevation of extracellular glutamate in the nucleus accumbens via a CB1 receptor mechanism. Sci Rep. (2018) 8:3686. doi: 10.1038/s41598-018-22087-1
74. Lu L, Xue Y, Steketee JD, Rebec GV, Sun W. Regulation of cocaine-induced reinstatement by group II metabotropic glutamate receptors in the ventral tegmental area. Psychopharmacol (Berl). (2012) 220:75–85. doi: 10.1007/s00213-011-2455-5
75. Mao L, Guo M, Jin D, Xue B, Wang JQ. Group III metabotropic glutamate receptors and drug addiction. Front Med. (2013) 7:445–51. doi: 10.1007/s11684-013-0291-1
76. Shimizu N, Duan SM, Hori T, Oomura Y. Glutamate modulates dopamine release in the striatum as measured by brain microdialysis. Brain Res Bull. (1990) 25:99–102. doi: 10.1016/0361-9230(90)90258-2
77. Bengtsson HJ, Kele J, Johansson J, Hjorth S. Interaction of the antidepressant mirtazapine with alpha2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo. Naunyn Schmiedebergs Arch Pharmacol. (2000) 362:406. doi: 10.1007/s002100000294
78. Devoto P, Flore G, Pira L, Longu G, Gessa GL. Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. Eur J Pharmacol. (2004) 487:105–11. doi: 10.1016/j.ejphar.2004.01.018
79. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. (2000) 12:1079–95. doi: 10.1046/j.1460-9568.2000.00982.x
80. Nakayama K, Sakurai T, Katsu H. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res Bull. (2004) 63:237–41. doi: 10.1016/j.brainresbull.2004.02.007
81. de Boer TH, Nefkens F, van Helvoirt A, van Delft AM. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. (1996) 277:852–60.
82. Cathala A, Devroye C, Maitre M, Piazza PV, Abrous DN, Revest JM, et al. Serotonin2C receptors modulate dopamine transmission in the nucleus accumbens independently of dopamine release: behavioral, neurochemical and molecular studies with cocaine. Addict Biol. (2015) 20:445–57. doi: 10.1111/adb.2015.20.issue-3
83. Matell MS, King GR. 5-HT3 receptor mediated dopamine release in the nucleus accumbens during withdrawal from continuous cocaine. Psychopharmacol (Berl). (1997) 130:242–8. doi: 10.1007/s002130050235
84. Yi SJ, Gifford AN, Johnson KM. Effect of cocaine and 5-HT3 receptor antagonists on 5-HT-induced (3H) dopamine release from rat striatal synaptosomes. Eur J Pharmacol. (1991) 199:185–9. doi: 10.1016/0014-2999(91)90456-z
85. Zayara AE, McIver G, Valdivia PN, Lominac KD, McCreary AC, Szumlinski KK. Blockade of nucleus accumbens 5-HT2A and 5-HT2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in rats. Psychopharmacol (Berl). (2011) 213:321–35. doi: 10.1007/s00213-010-1996-3
86. Nakamura S, Ago Y, Hayashi A, Itoh S, Kakuda M, Hashimoto H, et al. Modification of cocaine-induced behavioral and neurochemical effects by serotonin1A receptor agonist/antagonist in mice. Synapse. (2006) 60:479–84. doi: 10.1002/(ISSN)1098-2396
87. Przegaliñski E, Filip M. Stimulation of serotonin (5-HT)1A receptors attenuates the locomotor, but not the discriminative, effects of amphetamine and cocaine in rats. Behav Pharmacol. (1997) 8:699–706. doi: 10.1097/00008877-199712000-00004
88. Barrot M, Marinelli M, Abrous DN, Rougé-Pont F, Le Moal M, Piazza PV. Functional heterogeneity in dopamine release and the expression of Fos-like proteins within the rat striatal complex. Eur J Neurosci. (1999) 11:1155–66. doi: 10.1046/j.1460-9568.1999.00525.x
89. Hope BT, Nye HE, Kelz MB, Self DW, Iadarola MJ, Nakabeppu Y, et al. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron. (1994) 13:1235–44. doi: 10.1016/0896-6273(94)90061-2
90. Genova LM, Hyman SE. 5-HT3 receptor activation is required for induction of striatal c-Fos and phosphorylation of ATF-1 by amphetamine. Synapse. (1998) 30:71–8. doi: 10.1002/(ISSN)1098-2396
91. Pockros LA, Pentkowski NS, Conway SM, Ullman TE, Zwick KR, Neisewander JL. 5-HT(2A) receptor blockade and 5-HT(2C) receptor activation interact to reduce cocaine hyperlocomotion and Fos protein expression in the caudate-putamen. Synapse. (2012) 66:989–1001. doi: 10.1002/syn.21592
92. Szucs RP, Frankel PS, McMahon LR, Cunningham KA. Relationship of cocaine-induced c-Fos expression to behaviors and the role of serotonin 5-HT2A receptors in cocaine-induced c-Fos expression. Behav Neurosci. (2005) 119:1173–83. doi: 10.1037/0735-7044.119.5.1173
93. Ruskin DN, Marshall JF. Amphetamine- and cocaine-induced fos in the rat striatum depends on D2 dopamine receptor activation. Synapse. (1994) 18:233–40. doi: 10.1002/syn.890180309
94. Ampuero E, Rubio FJ, Falcon R, Sandoval M, Diaz-Veliz G, Gonzalez RE, et al. Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience. (2010) 169:98–108. doi: 10.1016/j.neuroscience.2010.04.035
95. Rogoz Z, Wrobel A, Dlaboga D, Dziedzicka-Wasylewska M. Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors. Pol J Pharmacol. (2002) 54:381–9.
96. Chanrion B, Mannoury la Cour C, Gavarini S, Seimandi M, Vincent L, Pujol JF, et al. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Mol Pharmacol. (2008) 73:748–57. doi: 10.1124/mol.107.041574
Keywords: multi-target drugs, cocaine, locomotor activity, locomotor sensitization, mirtazapine, pharmacotherapy
Citation: Barbosa-Méndez S and Salazar-Juárez A (2024) Mirtazapine decreased cocaine-induced c-fos expression and dopamine release in rats. Front. Psychiatry 15:1428730. doi: 10.3389/fpsyt.2024.1428730
Received: 06 May 2024; Accepted: 25 July 2024;
Published: 12 August 2024.
Edited by:
James K. Rowlett, University of Mississippi Medical Center, United StatesReviewed by:
Mariela Fernanda Perez, National University of Cordoba, ArgentinaChristina Jennifer Perry, Macquarie University, Australia
Copyright © 2024 Barbosa-Méndez and Salazar-Juárez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alberto Salazar-Juárez, azazel_vamp@yahoo.com.mx
†ORCID: Alberto Salazar-Juárez, orcid.org/0000-0003-1787-1657